The Clinical Dilemma of Anticoagulation Use in Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation

Rocco J. Cannistraro, James F Meschia

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of Review: This review highlights current management of patients with concomitant cerebral amyloid angiopathy (CAA) and atrial fibrillation (AF). We review quantifying risk of ischemic and hemorrhagic stroke as well as treatments to minimize future risk. Recent Findings: Ischemic stroke risk in AF can be quantified by CHA2DS2-VASc and assessing left atrial echocardiographic characteristics. Patients deemed not low risk by CHA2DS2-VASC should be anticoagulated. CAA increases intracranial hemorrhage risk. CAA biomarkers include cortical microbleeds (CMBs), cortical superficial siderosis (cSS), convexal subarachnoid hemorrhage (cSAH), and lobar intracerebral hemorrhage (ICH). CAA with prior lobar ICH has an annual recurrence rate of 8.9%. CAA with cSAH carries an even higher annual lobar ICH risk of 19%. CMBs are associated with a dose-dependent risk of ICH, which rises with OACs. Summary: In patients with AF, antithrombotics should be avoided in CAA with predominant ICH, cSS, or cSAH features. Those with ≥ 2 CMB require in-depth risk-benefit analysis using a multidisciplinary approach.

Original languageEnglish (US)
Article number106
JournalCurrent Cardiology Reports
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Cerebral Amyloid Angiopathy
Atrial Fibrillation
Cerebral Hemorrhage
Subarachnoid Hemorrhage
Siderosis
Stroke
Intracranial Hemorrhages
Biomarkers
Recurrence

Keywords

  • Anticoagulation
  • Antithrombotics
  • Atrial fibrillation
  • Cerebral amyloid angiopathy
  • Cerebral microbleeds
  • Intracerebral hemorrhage

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The Clinical Dilemma of Anticoagulation Use in Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation. / Cannistraro, Rocco J.; Meschia, James F.

In: Current Cardiology Reports, Vol. 20, No. 11, 106, 01.11.2018.

Research output: Contribution to journalReview article

@article{a2b35bd66a564a2db64893125704013c,
title = "The Clinical Dilemma of Anticoagulation Use in Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation",
abstract = "Purpose of Review: This review highlights current management of patients with concomitant cerebral amyloid angiopathy (CAA) and atrial fibrillation (AF). We review quantifying risk of ischemic and hemorrhagic stroke as well as treatments to minimize future risk. Recent Findings: Ischemic stroke risk in AF can be quantified by CHA2DS2-VASc and assessing left atrial echocardiographic characteristics. Patients deemed not low risk by CHA2DS2-VASC should be anticoagulated. CAA increases intracranial hemorrhage risk. CAA biomarkers include cortical microbleeds (CMBs), cortical superficial siderosis (cSS), convexal subarachnoid hemorrhage (cSAH), and lobar intracerebral hemorrhage (ICH). CAA with prior lobar ICH has an annual recurrence rate of 8.9{\%}. CAA with cSAH carries an even higher annual lobar ICH risk of 19{\%}. CMBs are associated with a dose-dependent risk of ICH, which rises with OACs. Summary: In patients with AF, antithrombotics should be avoided in CAA with predominant ICH, cSS, or cSAH features. Those with ≥ 2 CMB require in-depth risk-benefit analysis using a multidisciplinary approach.",
keywords = "Anticoagulation, Antithrombotics, Atrial fibrillation, Cerebral amyloid angiopathy, Cerebral microbleeds, Intracerebral hemorrhage",
author = "Cannistraro, {Rocco J.} and Meschia, {James F}",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s11886-018-1052-1",
language = "English (US)",
volume = "20",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "11",

}

TY - JOUR

T1 - The Clinical Dilemma of Anticoagulation Use in Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation

AU - Cannistraro, Rocco J.

AU - Meschia, James F

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose of Review: This review highlights current management of patients with concomitant cerebral amyloid angiopathy (CAA) and atrial fibrillation (AF). We review quantifying risk of ischemic and hemorrhagic stroke as well as treatments to minimize future risk. Recent Findings: Ischemic stroke risk in AF can be quantified by CHA2DS2-VASc and assessing left atrial echocardiographic characteristics. Patients deemed not low risk by CHA2DS2-VASC should be anticoagulated. CAA increases intracranial hemorrhage risk. CAA biomarkers include cortical microbleeds (CMBs), cortical superficial siderosis (cSS), convexal subarachnoid hemorrhage (cSAH), and lobar intracerebral hemorrhage (ICH). CAA with prior lobar ICH has an annual recurrence rate of 8.9%. CAA with cSAH carries an even higher annual lobar ICH risk of 19%. CMBs are associated with a dose-dependent risk of ICH, which rises with OACs. Summary: In patients with AF, antithrombotics should be avoided in CAA with predominant ICH, cSS, or cSAH features. Those with ≥ 2 CMB require in-depth risk-benefit analysis using a multidisciplinary approach.

AB - Purpose of Review: This review highlights current management of patients with concomitant cerebral amyloid angiopathy (CAA) and atrial fibrillation (AF). We review quantifying risk of ischemic and hemorrhagic stroke as well as treatments to minimize future risk. Recent Findings: Ischemic stroke risk in AF can be quantified by CHA2DS2-VASc and assessing left atrial echocardiographic characteristics. Patients deemed not low risk by CHA2DS2-VASC should be anticoagulated. CAA increases intracranial hemorrhage risk. CAA biomarkers include cortical microbleeds (CMBs), cortical superficial siderosis (cSS), convexal subarachnoid hemorrhage (cSAH), and lobar intracerebral hemorrhage (ICH). CAA with prior lobar ICH has an annual recurrence rate of 8.9%. CAA with cSAH carries an even higher annual lobar ICH risk of 19%. CMBs are associated with a dose-dependent risk of ICH, which rises with OACs. Summary: In patients with AF, antithrombotics should be avoided in CAA with predominant ICH, cSS, or cSAH features. Those with ≥ 2 CMB require in-depth risk-benefit analysis using a multidisciplinary approach.

KW - Anticoagulation

KW - Antithrombotics

KW - Atrial fibrillation

KW - Cerebral amyloid angiopathy

KW - Cerebral microbleeds

KW - Intracerebral hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=85053285055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053285055&partnerID=8YFLogxK

U2 - 10.1007/s11886-018-1052-1

DO - 10.1007/s11886-018-1052-1

M3 - Review article

VL - 20

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 11

M1 - 106

ER -